Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
Development of therapeutics for brain disorders is one of the more difficult challenges to be overcome by the scientific community due to the inability of most molecules to cross the blood-brain barrier (BBB). Antibody-conjugated nanoparticles are drug carriers that can be used to target encapsulated drugs to the brain endothelial cells and have proven to be very promising. They significantly improve the accumulation of the drug in pathological sites and decrease the undesirable side effect of drugs in healthy tissues. We review the systems that have demonstrated promising results in crossing the BBB through receptor-mediated endocytic mechanisms for the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease.
LEBABE, Department of Chemical Engineering, Faculty of Engineering of the University of Porto, 4200-465 Porto, Portugal.
Joana A
JA
Loureiro
Bárbara
B
Gomes
Manuel A N
MA
Coelho
Maria
M
do Carmo Pereira
Sandra
S
Rocha
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001812:Blood-Brain Barrier / Q000378:metabolism*; D004339:Drug Compounding / Q000379:methods; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D053769:Nanocapsules / Q000737:chemistry* / Q000648:ultrastructure; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D053769:Nanocapsules; D018696:Neuroprotective Agents
Alzheimer’s disease; PLGA nanoparticles; Parkinson’s disease; blood–brain barrier; liposome; monoclonal antibody; targeting